AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and …
Maxim Group analyst Jason Kolbert weighed in today with his views on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), following the news that the company has commenced the promotion …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZSׁ) announced that it has started promoting Saizen® [somatropin (rDNA origin) for injection] in 25 territories in the United States, …
Maxim Group’s healthcare analyst Jason Kolbert came out with a research report on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) following the news that the company has reached its …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it has received notice from the NASDAQ Listing Qualifications Department (“NASDAQ”) determining that the Company is eligible …
Maxim Group analyst Jason Kolbert came out with a research report on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after visiting with management in South Carolina and reviewing the company …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it has received written scientific advice from the European Medicines Agency (“EMA”) regarding the further development …
H.C.
